Phase 2 N=64 A Study for Participants With Small-Cell Lung Cancer
Small Cell Lung Cancer
Primary: Part A: Percentage of Participants Achieving an Overall Response (Overall Response Rate) — 2.6 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=50 Ranolazine Among Unrevascularized Chronic Stable Angina Patients
Angina
Primary: Seattle Angina Questionnaire Score Change From Baseline to 16 Weeks — 48; 50; 40; 60 units on a scale — p=>0.05
Phase 2 N=84 GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection
Skin Infections, Bacterial
Primary: Number of Participants With Any Adverse Events (AE) and Serious Adverse Events (SAE) — 49; 20; 1; 1 Participants
Phase 2 N=39 A Study of LY2523355 in Participants With Breast Cancer
Metastatic Breast Cancer
Primary: Change in Tumor Size (CTS) From Baseline to the End of Cycle 2 — -0.0; -0.1 log ratio of end of Cycle 2 to baseline — p=0.344
Phase 2 N=154 A Study of LY2541546 in Women With Low Bone Mineral Density
Osteoporosis
Primary: Change From Baseline to 52 Week Endpoint in Lumbar Spine Bone Mineral Density (BMD) — 0.065; 0.115; 0.142; 0.054 g/cm^2
Phase 2 N=103 A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Ovarian Cancer · Non Small Cell Lung Cancer · Prostate Cancer
Primary: Percentage of Participants With a Complete Response (CR) or Partial Response (PR) — 0; 0; 0; 0 percentage of participants
Phase 2 N=90 Trial of Oral Valproic Acid for Retinitis Pigmentosa
Retinitis Pigmentosa
Primary: Mean Change in Visual Field Area From Baseline to 52 Weeks--III4e Isopter — -122.9; -112.0; -293.7; -237.1 Visual field area (degrees squared) — p=0.035
Phase 2 N=61 Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable · Leukemia · Lymphoma
Primary: Number of Participants With Adverse Events — 1; 31; 1; 22 Participants
Phase 2 N=25 Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma
Leukemia · Lymphoma, Non-Hodgkin
Primary: Tumor Apoptosis — 7 Participants
Phase 2 N=267 A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)
Non-small Cell Lung Carcinoma
Primary: Part 2 Cohorts G+ and G-: Objective Response Rate (ORR) — 55.0; 28.6 Percentage of Participants — p=0.0016
Phase 2 N=63 Development of Vitamin D as a Therapy for Breast Cancer - Phase 2
Breast Cancer
Primary: Correlation of Vitamin D Levels, Prognostic Factors, and Gene Expression Profile in Patients With Breast Cancer — 0; 0; 0; 0 percentage of participants
Phase 2 N=19 Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC
MDS · Immunodeficiency · GATA2
Primary: Days to Neutrophil Engraftment — 12 Days
Phase 2 N=22 EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Fallopian Tube Carcinoma · Primary Peritoneal Carcinoma · Recurrent Ovarian Carcinoma
Primary: Patients Who Survive Progression-free for at Least 6 Months — 6; 14 Participants
Phase 2 N=132 A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
Metastatic Breast Cancer
Primary: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) — 19.7 Percentage of participants
Phase 2 N=26 An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
Acute Myeloid Leukemia (AML) · Acute Lymphoblastic Leukemia (ALL) · Myelodysplastic Syndrome (MDS)
Primary: Effect of CPX-351 on Cardiac Ventricular Repolarization (QTcF) — 0.6; -1.2; 4.3; 5.3 msecs